On August 16, 2023, a three-judge panel of the Fifth Circuit Court of Appeals issued an opinion in the ongoing litigation regarding the U.S. Food & Drug Administration (“FDA”) approval and regulation of mifepristone (brand name Mifeprex), a drug used in medically induced abortions. The panel vacated in part and affirmed in part a decision…Read More
Federal Court of Appeals Panel Issues Ruling in Litigation Challenging FDA Approval of Mifepristone
Posted on August 31, 2023 in Health Law News, Litigation Analysis
Published by: Hall Render